|Study Description:||There are 5 parts to this clinical research study. MD Anderson will be |
taking part in Parts B, D, and F. This consent form will cover Parts B, D, and
The goal of Part B is to further test the highest tolerable dose of MK-3475
that was found in Part A when given to patients with melanoma. The safety of
this drug will also be studied.
The goal of Part D is to study 2 dose levels of MK-3475 when given to patients
The goal of Part F is to study 2 dose levels of MK-3475 when given to patients
with lung cancer.
MK-3475 is a drug that includes a protein naturally created by living cells.
It is designed to help the body's natural defense system react against tumors
by blocking proteins that cancers cells create to "turn off" the body's immune
This is the first study using MK-3475 in humans.